BOULDER, Colo.–(Small business WIRE)–Jan 5, 2021–
Biodesix, Inc. (Nasdaq: BDSX), a major knowledge-pushed diagnostic methods company with a target in lung sickness, currently declared that Ryan Siurek has joined the business as Chief Accounting Officer reporting to Ms. Robin Harper Cowie, Chief Fiscal Officer.
“I am extremely delighted to welcome Ryan as our new Main Accounting Officer. His in depth finance and accounting management working experience will assistance Biodesix mature as we enter our upcoming stage of progress in 2021 and beyond,” mentioned Ms. Cowie.
Prior to joining the Enterprise, Mr. Siurek served as Senior Vice President, Main Accounting Officer and Controller of Vail Resorts, Inc. from April 2016 to September 2020. From January 2009 to April 2016, Mr. Siurek served as an government at Dash Company the place he held many accounting and finance roles which includes Vice President Controller & Chief Accounting Officer and Vice President, Divisional Chief Money Officer for the prepaid and wholesale and organization methods divisions. Mr. Siurek earned a BBA & MS in Accounting from Texas A&M University, and is a Licensed Community Accountant. Mr. Siurek also serves as a member of the American Institute of Licensed Public Accountants (AICPA) Financial Reporting Govt Committee (FinREC), a senior committee centered on monetary reporting.
Biodesix is a leading diagnostic firm with a emphasis in lung sickness. The Company develops diagnostic checks addressing critical clinical questions by combining multi-omics by means of the energy of artificial intelligence. Biodesix is the 1st business to provide six non-invasive checks for patients with conditions of the lung. Biodesix introduced the SARS-CoV-2 ddPCR™ exam and the Platelia SARS-CoV-2 Whole Ab in response to the international pandemic and virus that impacts the lung and causes COVID-19. The blood-dependent Biodesix Lung Reflex® tactic for lung most cancers people integrates the GeneStrat® and VeriStrat® exams to support treatment method choices with benefits in 72 hrs, expediting time to treatment. The blood-primarily based Nodify Lung™ nodule danger assessment screening technique, consisting of the Nodify XL2® and the Nodify CDT™ exams, evaluates the hazard of malignancy in incidental pulmonary nodules, enabling physicians to much better triage patients to the most proper training course of action. Biodesix also collaborates with many of the world’s top biotechnology and pharmaceutical firms to solve complicated diagnostic troubles in lung disease. For far more data about Biodesix, visit biodesix.com.
Be aware Concerning Ahead-Wanting Statements
This press launch might have forward-searching statements that entail substantial dangers and uncertainties for functions of the safe harbor delivered by the Non-public Securities Litigation Reform Act of 1995. All statements contained in this press release other than statements of historic truth, are ahead-looking statements. The terms “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “plan,” “expect,” “predict,” “potential,” “opportunity,” “goals,” or “should,” and related expressions are supposed to recognize ahead-on the lookout statements. These types of statements are based mostly on management’s present-day anticipations and involve dangers and uncertainties. True outcomes and functionality could vary materially from people projected in the forward-seeking statements as a final result of several variables. Biodesix has based mostly these ahead-looking statements mostly on its current expectations and projections about long term functions and developments. These ahead-looking statements are issue to a range of risks, uncertainties and assumptions. Furthermore, Biodesix operates in a competitive and swiftly changing ecosystem. New dangers emerge from time to time. It is not possible for its management to forecast all threats, nor can it evaluate the effects of all things on its business or the extent to which any element, or combination of aspects, may perhaps result in true effects to vary materially from individuals contained in any forward-searching statements it may possibly make. Biodesix undertakes no obligation to revise or publicly launch the benefits of any revision to these kinds of ahead-looking statements, other than as essential by law. Given these threats and uncertainties, readers are cautioned not to place undue reliance on this kind of forward-looking statements. All ahead-looking statements are experienced in their entirety by this cautionary statement.
Look at resource edition on businesswire.com:https://www.businesswire.com/news/residence/20210105005231/en/
Speak to: Jordona Jackson Smith
Keyword: UNITED STATES NORTH The united states COLORADO
Business Search phrase: Specialist Expert services ONCOLOGY Overall health FINANCE PHARMACEUTICAL BIOTECHNOLOGY
Source: Biodesix, Inc.
Copyright Business Wire 2021.
PUB: 01/05/2021 06:00 AM/DISC: 01/05/2021 06:00 AM